You are logged in as Log out

Improved Care Through Enhanced Clinical Decisions

by Sowmya Josyula, MD MPH

Powered by prescriptive analytics, Klincis's products allow physicians to visualize the outcome of important treatment modalities at the point of care.

New York, NY Health Information Technology

Share this project and help them win!

All Team Company Patients Physicians Mission Supporters

About this project

The problem we solve:
Medical errors: they’re an incalculable problem in every hospital and clinic despite the well-intentioned protocols set up to prevent them. Errors are costly in more ways than one. There’s the financial aspect, yes, but the cost to human life and safety is vast. In fact, hospital errors comprise the fourth leading cause of death after heart attack, cancer, and stroke. They are sometimes classified as “unintentional accidents” and come in many forms. For instance, overprescription of medications and procedures are considered a type of medical error, as they can lead to patient safety issues and costly impacts to an institution’s bottom line. Let’s take blood transfusions as an example: more than 5 million people get blood transfusions per year--20% to 50% outside of clinical guidelines. While transfusions are undeniably life-saving in the right situations, they can also significantly prolong length of stay, increase mortality by 0.5%, and cost $1-$3 million per year (for a 400-bed hosp

About our solution:
The same physician from our earlier example now has a link in the EMR for H?mcis. H?mcis is also triggered by events such as a reduction in hemoglobin or a change in blood pressure or heart rate, etc. All relevant labs (hemoglobin, creatinine levels, vitals) are available on a single screen for the physician to review--all at the point of care. The logic behind H?mcis’s predictive models recommends to the physician the odds of outcomes such as length of stay, cost of stay, complication risk, etc, for transfusion treatment. In this case example, a different decision would have been made due to the available information from H?mcis; the physician would have decided to not transfuse based on higher risk of complications for that particular patient. The physician also has a pictographic tool with H?mcis to enable him to discuss the decision with the patient. The analytics dashboard is helpful for physicians and administrators to compare aggregate outcome trends by patients and doctors for
Progress to date: Our preliminary data from a major hospital in Manhattan showed that H?mcis can reduce 19% of excess orders. We are a startup focused on leveraging data and analytics to improve patient outcomes. To that end, we have developed the beta version of our product.

About Our Team

Dr. Sowmya Josyula, MD MPH
Internal Medicine, Resident
Medical school: Gandhi Medical College
Bio: I am a Clinical Research Scientist with a primary focus in public health and informatics. I am interested in both the development of preventive medicine and the application of information systems to solve medical problems. Prior to starting the company, I earned her MPH degree from New York University and MD from Gandhi Medical College in India. I am currently PGY-1 at St. Barnabas Health System.
Title: MD

About Team Members

Om. Vadlapatla
Biography: Om Vadlapatla is the founder and CEO of Klincis. He has spent more than a decade working in the areas of development, technology, and business strategy consulting with numerous organizations to improve technology systems and optimize businesses. Om has experience in verticals as diverse as healthcare, telecommunications, IT, multimedia content development, and semiconductors and he is passionate about bridging the gap between technology processes and business process improvement. Om has a Master

About Our Company

Location: New York, New York
Twitter: @klinciscds
Other link:
Product stage: proto
Sales: Working on it
Employees: 1-2

How We Help Patients

Risk scores bridge the data gap and bring objective decision-making to clinical care, using the best available science to deliver actionable information. They provide clear probabilities of both short- and long-term outcomes based on large, diverse data sets, giving information that is unique to each individual patient. This eliminates the need for “guessing” and increases the amount of time physicians can spend with their patients at the bedside. They increase accountability and transparency, optimize blood product utilization, and open the door for shared decision-making. Incorporation of clear visual representations of the benefits and risks of transfusions in a patient-friendly format allows the physician and patient to look at the information together and jointly decide on the best option. The need for this study has been recently validated at the HIMSS and AABB conferences by talking to more than 200 physicians, administrators, and patient advocacy groups. With the research exper

How We Help Physicians

For most health conditions, there is no “gold standard,” and most medical decisions have multiple clinically appropriate options. H?mcis, by providing odds on important patient outcomes for the patient being treated, eliminates the need for “guessing” and increases the amount of time physicians can spend with their patients at the bedside. They increase accountability and transparency, optimize blood product utilization, and open the door for shared decision-making. The calculated risk scores are provided as a decision support with a recommendation within the physician’s workflow at the point of care. This saves time, helps meet hospital metrics, and alleviates litigation concerns by knowing each decision was well-informed and evidence-based. Similar scores are being developed to be applied to hospital-acquired infections, antibiotics, pain management, and other fields, providing a wide platform for CDSS and physician-patient engagement.

Challenge Mission

Mission: The predictive models are built by an amalgamation of clinical, mathematical, technology acumen and understands the importance of incorporating the clinical perspective thus aligning with AMA's vision
Use of funds: 1. Validate our preliminary models 2. A pilot test will be conducted to determine the system’s clinical validity and effectiveness.
Intellectual Property Status: N/A
FDA Status: We do not expect to be required to need FDA approval for our clinical decision support system. Recent FDA policy stand on CDSS is available at the following link: Guidelines suggest that our application will be of Class I status and will not require further risk assessment or regulatory oversight.
Personal Message: The need for our product was validated by 276 clinicians and hospital administrators; a major health system’s pathology data showed that H?mcis can reduce 19% of excess orders. We are in negotiations with two other major health systems to close sales as early adopters. Please support the mission to bring about a change.














Sowmya Josyula, MD MPH
Gandhi Medical College

See Full Proflle
Contact Us